Home > Insider Trading > Filing (0000820081-14-000005)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
820081	Cambrex Corp	CBM	Pharmaceutical Preparations (2834)	222476135

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1227835	Gregory Sargen	One Meadowlands Plaza East Rutherford NJ 07073	Evp & Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-02-18	8,500	$13.75	41,819	No	4	M	Direct
Common Stock	Acquisiton	2014-02-18	30,000	$5.51	71,819	No	4	M	Direct
Common Stock	Disposition	2014-02-18	38,500	$21.66	33,319	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2014-02-18	8,500	$0.00	8,500	$13.75
Common Stock	Stock Option (Right to Buy)	Disposition	2014-02-18	30,000	$0.00	30,000	$5.51

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2014-07-26	No	4	M	Direct
50,000		2015-04-23	No	4	M	Direct

Footnotes

The option, representing a right to purchase a total of 8,500 shares, became exercisable in four equal annual installments beginning on July 26, 2008, which was the first anniversary of the date on which the option was granted.
The option, representing a right to purchase a total of 100,000 shares, became exercisable in four equal annual installments beginning on April 23, 2009, which was the first anniversary of the date on which the option was granted.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.45 to $21.86, inclusive. The reporting person undertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.